In lung cancer, acquired resistance following treatment with EGFR‐targeted therapies has been thoroughly examined using patient samples, in which additional gene mutations and/or hyper‐amplification in EGFR (e.g., T790M in EGFR) as well as downstream genes including MET, c‐ErbB‐2/HER2, RAS/MAPK, and cyclins/CDKs were identified.18 This evidence concerns the gene EGFR and lung cancer.